Nonclinical investigations of a novel heart-type fatty acid–binding protein ligand, [18F]LUF: three-lot process validation, safety assessment, and radiation dosimetry
[<sup>18</sup>F]LUF shows acceptable pharmacological safety at the dose required for adequate PET imaging. The potential risks associated with [<sup>18</sup>F]LUF injection are well within the acceptable dose limits.
Authors
- Muneyuki Sakata (ORCID: https://orcid.org/0000-0001-8161-0916)
- Tetsuro Tago (ORCID: https://orcid.org/0000-0002-9545-0922)
- Hiroshi Yoshino (ORCID: https://orcid.org/0000-0002-7381-5943)
- Takeshi Komoda (ORCID: https://orcid.org/0000-0003-3609-7716)
- Jun Toyohara (ORCID: https://orcid.org/0000-0003-4721-405X)
- Masahiko Ito (ORCID: https://orcid.org/0000-0001-7020-7312)
Institutions
- Musashino University (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1186/s41181-025-00404-0
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00